TMB and MSI are predictors of immunotherapy efficacy, and our results suggest NMUR1 could be added to this repertoire, especially considering its positive correlation with immune checkpoint protein LAG3 and CTLA4, indicative of a prognostic and therapeutic biomarker for CRC. Here, CTLA4 is linked to colorectal carcinoma.